Vanessa Caceres

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

April 16 2020

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

Dry eye disease and allergic conjunctivitis are two flourishing markets within ophthalmology. The dry eye market is expected to climb to $5.1 billion by the ...
Read More
Ranibizumab More Cost-Effective Than PRP

February 5 2020

Ranibizumab More Cost-Effective Than PRP

The use of ranibizumab 0.5 mg for proliferative diabetic retinopathy (PDR) compared with panretinal photocoagulation (PRP) appeared to be more cost effective for patients with ...
Read More
CorneaGen Aims to End Corneal Blindness

December 4 2019

CorneaGen Aims to End Corneal Blindness

CorneaGen’s approach to treating corneal blindness is to prevent it from ever occurring, said Monty Montoya, president and CEO, who added no other organization has ...
Read More